Journal article · 2026

Lp(a)-Reducing Agent Pelacarsen Misses the Mark in Phase 3—Now What?

Jennifer Abbasi

JAMA, 336(18), 1587 · Published 16 October 2026 · DOI 10.1001/jama.2026.20002

View at the publisherCite this paper

In brief

“Lp(a)-Reducing Agent Pelacarsen Misses the Mark in Phase 3—Now What?” is a 2026 journal article by Jennifer Abbasi, published in JAMA. OpenAlex counts 1 citations as of 17 November 2026, which puts it in the top 9% of works published in 2026 by citations. The publisher's version is not open access, and OpenAlex records no free legal copy.

Citations
1
Most cited in
2026 (1)
Field-weighted impact
3.46
Authors
1

Abstract

This Medical News article discusses the top-line results from the Lp(a)HORIZON trial, which investigated lipoprotein(a) lowering to reduce major adverse cardiovascular events. Read the full abstract at the publisher.

Excerpt. This paper is not open access.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Abbasi, J. (2026). Lp(a)-Reducing Agent Pelacarsen Misses the Mark in Phase 3—Now What? JAMA, 336(18), 1587. https://doi.org/10.1001/jama.2026.20002

MLA 9

Abbasi, Jennifer. “Lp(a)-Reducing Agent Pelacarsen Misses the Mark in Phase 3—Now What?” JAMA, vol. 336, no. 18, 2026, p. 1587. https://doi.org/10.1001/jama.2026.20002.

Chicago

Abbasi, Jennifer. 2026. “Lp(a)-Reducing Agent Pelacarsen Misses the Mark in Phase 3—Now What?” JAMA 336 (18): 1587. https://doi.org/10.1001/jama.2026.20002.

Harvard

Abbasi, J. (2026) ‘Lp(a)-Reducing Agent Pelacarsen Misses the Mark in Phase 3—Now What?’, JAMA, 336(18), p. 1587. doi:10.1001/jama.2026.20002.

IEEE

J. Abbasi, “Lp(a)-Reducing Agent Pelacarsen Misses the Mark in Phase 3—Now What?,” JAMA, vol. 336, no. 18, p. 1587, 2026, doi: 10.1001/jama.2026.20002.

BibTeX

@article{abbasi2026reducing,
  title     = {{Lp(a)-Reducing Agent Pelacarsen Misses the Mark in Phase 3—Now What?}},
  author    = {Abbasi, Jennifer},
  journal   = {JAMA},
  year      = {2026},
  volume    = {336},
  number    = {18},
  pages     = {1587},
  doi       = {10.1001/jama.2026.20002},
  url       = {https://doi.org/10.1001/jama.2026.20002}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health

  • pelacarsen
  • lipoprotein(a)
  • Lp(a) lowering
  • major adverse cardiovascular events
  • PCSK9 inhibitors

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Abbasi, J. (2026). Lp(a)-Reducing Agent Pelacarsen Misses the Mark in Phase 3—Now What? JAMA, 336(18), 1587. https://doi.org/10.1001/jama.2026.20002

How many times has this paper been cited?

1 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.

Who wrote this paper?

Jennifer Abbasi.

What is the DOI of this paper?

10.1001/jama.2026.20002, permanently at https://doi.org/10.1001/jama.2026.20002. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.